In the $10 million June/17 financing, HL and Eastern bought a combined $5.3 million by Private Placement while $4.6 million worth were sold to subscribers via a Base Shelf Prospectus. The HL and Eastern shares had a 4 month hold and the rest were treated the same as the current offering.

"Each equity unit consists of one common share and one common share purchase warrant. Each warrant is exercisable at a price of $2.05 per underlying common share for a period of four years from the closing of the offering. The units purchased pursuant to the overnight marketed equity offering were qualified for sale by way of a prospectus supplement dated June 13, 2017 to Resverlogix's base shelf prospectus dated October 1, 2015 (together, the "Prospectus"), which was filed in each of the Provinces of Canada, other than Quebec. The units purchased by Eastern and Hepalink were purchased pursuant to a private placement and are subject to a four month hold period."